Market Overview - The Asia-Pacific Pharmaceutical Contract Manufacturing Organization (CMO) Market is projected to grow from an estimated USD 59.97 billion in 2025 to USD 91.18 billion by 2030, reflecting a compound annual growth rate (CAGR) of 8.74% [2] - The market landscape is highly fragmented, with large pharmaceutical firms increasingly outsourcing production to CMOs for cost efficiency and expertise [6] Regional Insights - China's competitive advantage in the CMO market is attributed to low labor costs, tax incentives, and favorable currency valuation, which help reduce manufacturing expenses [3] - India is attracting Japanese pharmaceutical investments through favorable foreign direct investment policies, enhancing its domestic manufacturing landscape [8] - Japan's CMO sector has experienced a 30% growth due to regulatory changes that separate manufacturing from sales [8] - Australia faces challenges due to pricing and reimbursement volatility but benefits from its geographical proximity to South Asian markets [8] Market Dynamics - The demand for injectable drugs, particularly for rapid-acting oncology treatments, presents significant growth opportunities within the market [8] - Prolific late-stage clinical trials, especially in cancer therapies, are expected to drive market growth, with anti-cancer drugs making up nearly half of the developmental pipeline [8] - Outsourcing of biologic formulations to CMOs is common as major pharmaceutical companies focus on discovering and developing new drug modalities [8] Industry Developments - Recent expansions by companies such as Jubilant Biosys in India and Boehringer's capacity increase in China highlight strategic collaborations aimed at enhancing market share [6] - New policies in India allowing certain drug studies without late-stage clinical trials lead to considerable cost savings, further strengthening its appeal for pharmaceutical production [8] Challenges - The COVID-19 pandemic has disrupted global supply chains, necessitating strategic responses to inventory management, particularly as China is a key supplier of essential raw materials [8] - Increasing lead times and logistics costs, along with stringent regulatory requirements, pose challenges for the CMO market [14]

米兰, April 29, 2025 (GLOBE NEWSWIRE) -- 全球领先的制药合同研发生产组织 (CDMO) Olon Group 宣布任命 Jérôme Bédier 为其法国子公司的首席执行官，同时任命 Andrea Conforto 担任旗下专注于生物制剂 CDMO 服务的业务部门——Olon Biotech CDMO 事业部的市场和销售副总裁。 上述任命进一步巩固了 Olon 在抗体药物偶联物 (ADC)、高活性原料药 (HPAPI) 及微生物生物生产领域拓展能力的战略布局。 ADC、HPAPI 与微生物生物生产一体化愿景 凭借全新的领导层架构，Olon Group 正加速推进其完全一体化 ADC 服务的开发，涵盖从细胞系开发 (CLD) 到药物产品生产的完整价值链，包括有效载荷和连接子生产。 这一综合方案为生物技术公司和制药企业提供无缝衔接的 CDMO 解决方案，助力下一代靶向疗法的研发生产。 Olon Group 还充分利用其近期对意大利罗达诺工厂的投资，这些投资不仅提升了其 HPAPI 的生产能力，也与其在复杂生物制药生产领域的长期承诺高度契合。 与此同时，Olon 正在加强其微生 ...